A joint program of the Johns Hopkins University and the National Cancer Institute
- Information For Applicants
- To apply: Applicants for Fellowship training beginning in July 2015 will apply via the Electronic Residency Application Service (ERAS). Apply Now.
- Questions? Please feel free to contact Gladys Valencia Novak, Fellowship Coordinator at (410) 614-5055 or email.
Fellowship Program Overview
Meet Our Fellows
The fellowship is designed to provide clinical and research exposure that allows for the development of subspecialist academicians adept in laboratory and/or clinical research, coupled with superior patient management skills. Training in Pediatric Oncology at Johns Hopkins University (JHU) is under the supervision of Dr. Ido Paz-Priel, Director of Fellowship Training. Training in Pediatric Hematology is under the direction of Dr. Jeffrey Keefer, Co-Director of Fellowship Training at JHU. Training in Pediatric Oncology at the National Cancer Institute (NCI), National Institutes of Health (NIH) is under the direction of Dr. Kristin Baird, Co-Director of Fellowship Training. Six fellows per year are selected via the National Residency Matching Program (NRMP). The first year of the fellowship is largely clinical with inpatient and outpatient exposure at JHU and the NIH. The second and third years are focused research years allowing for training in laboratory and/or clinical research.
The first year of fellowship will include:
- JHU Hematology Inpatient Service
- JHU Hematology Outpatient Service
- JHU Hematology and Clinical Laboratory Training
- JHU Oncology Service (Oncology and BMT)
- NIH Leukemia, Lymphoma and BMT
- NIH Solid Tumor and Experimental Therapeutics
- Continuity Clinic (weekly during selected rotations)
JHU Hematology Inpatient Service: This rotation is designed to educate fellows in the treatment of a wide range of hematologic conditions including hemoglobinopathies, coagulopathies, ITP, anemias, and patients requiring chronic transfusions. Fellows are responsible for supervising the care of all inpatients on the hematology service. Additional exposures include teaching in the preparation and interpretation of blood smears and bone marrows.
JHU Hematology Outpatient Service: Exposures during this rotation in hematology include the evaluation of outside referrals for a wide range of hematologic conditions, and participation in the longitudinal management of children with defined hematologic disorders. Fellows are also responsible for the management of patients undergoing erythrocytopheresis.
JHU Hematology Laboratory Training: Rotations are spent in hematology laboratories to provide exposure to Coagulation Lab, Hemoglobinopathies/Routine Hematology, and Blood Bank. These laboratory exposures are designed to familiarize the fellow with the gamut of laboratory studies required for hematologic interpretation and diagnoses. Fellows participate in supporting conferences (e.g. coagulation conference).
JHU Oncology Service: Fellows work on the Oncology Team followed by the BMT Team. The Oncology Team fellow supervises the care of newly diagnosed patients, patients with therapy-associated complications, and patients receiving inpatient chemotherapy. Exposure to the broad range of oncologic diagnoses is anticipated. Outpatient exposures during this time include the evaluation of outpatient referrals, assessment of neuro-oncology patients, and evaluation of patients with late-effects related to prior cancer treatment. During the BMT Team rotation, fellows are responsible for the oversight of patients undergoing BMT, as well as patients admitted for complications related to prior transplantation. Outpatient exposures include the evaluation of patients being considered for BMT as well as some participation in the ongoing management of established BMT patients. Fellows have responsibility for the supervision of houseofficers who rotate on the service each month. Newly diagnosed patients are assigned to the fellow for ongoing continuity in the outpatient setting.
NIH Inpatient/Outpatient “Team A”: Fellows care for patients with Leukemia, Lymphoma, Stem Cell Transplant and Genetic Tumor Predisposition Syndromes.
NIH Inpatient/Outpatient “Team B”: Fellows are responsible for clinical care of patients with solid tumors, Neuro-oncologic conditions, and Pharmacology and Experimental Therapeutics patients.
The NIH “Team” model allows fellows to care for patients in both the outpatient and inpatient setting. Fellows evaluate all new referrals and provide comprehensive care for patients undergoing treatment or evaluation. In addition, the Pediatric Oncology Branch (POB) offers a consult and second-opinion service and fellows are responsible for the initial evaluation of these patients. Finally, the fellows are responsible for organizing and presenting complicated patients at weekly branch rounds, tumor boards and case conferences.
The advantage of the team model is to provide fellows with a more comprehensive experience in clinical research. Fellows follow patients for an extended period of time, participate in protocol meetings and learn NCI clinical trials in depth. Fellows are directly supervised by the attending physician and have extensive interactions with research protocol principal investigators. This interaction emphasizes the important connection between research, education and patient care.
Continuity Clinic: Fellows are required by the subspecialty board to maintain a continuity exposure during their fellowship. All fellows have continuity clinic at JHU, which is composed of oncology and hematology patients acquired during their inpatient and outpatient rotations at JHU. During the first year of fellowship, continuity clinic is integrated into the various rotations. In subsequent years of training, the fellow individually tailors their continuity experience which occurs at JHU regardless of research locale.
Vacation: Approximately four weeks of vacation are provided per year.
Training in the Second and Third Years
The second and third years of fellowship are designed to be focused research years. Among the many advantages of the merger is the wide range of research opportunities available to each fellow. Laboratory and clinical research at both institutions are unparalleled and the merger allows the fellow to choose among almost unlimited research options. To ensure maximum productivity, clinical responsibilities are limited. The remainder of this protected time is spent pursuing a research initiative tailored to the specific interests of the fellow. Decisions regarding the appropriate locale for research training are made in concert with faculty advisors and fellowship directors. Many fellows focus on basic science research, either in the laboratories of faculty members in Pediatric Hematology/Oncology at either institution or in other appropriate laboratory settings. Fellows are free to choose among the many laboratories at JHU and throughout the intramural NIH community. Selected fellows who have chosen to focus on clinical research may apply to the clinical research program at the JHU Bloomberg School of Public Health, where formal training and a clinical research experience is provided in the expectation of fellows obtaining a PhD in Clinical Investigation. Fellows may also apply for advanced studies in clinical research through an NIH/POB program providing up to three years of additional research training following the completion of the initial three years of fellowship training.
Effective mentoring is critical to the success of fellows both during training and to successfully meet the career goals following the completion of training. Each fellow has multiple mentors to assist in professional development:
1. Fellowship leadership has broad overview responsibilities for being certain that fellows have a successful fellowship experience. They are available at all times.
2. Faculty Advisors: Each fellow selects two faculty advisors (one each at JHU and the NIH) during the first year of fellowship.
3. Research Mentors: Once a fellow has selected a research mentor for the 2nd and 3rd years of training, that person will obviously play a major role in research and career mentorship.
4. Scholarship Oversight Committee: All fellows have a committee (much like a thesis committee) that is responsible for research oversight, and eventually, to certify that the fellow has achieved a "meaningful accomplishment in research".
Primary Clinical Faculty and Research Interests:
|Faculty Member||Institution||Research Focus|
|Robert J. Arceci, MD, PhD||JHU||Development of novel targets and immunotherapies for leukemias and histocytic disorders|
|Kristin Baird, MD||NIH|
Biology and treatment of chronic graft -vs.-host disease
|Vandy Black, MD||JHU||Pain and sickle cell disease|
|Patrick Brown, MD||JHU||Molecularly targeted therapies for leukemia|
|Emily Barron-Casella, PhD||JHU||Basic and translational studies of sickle cell disease|
|James Casella, MD||JHU||Treatment, proteomics and genetics of central nervous system vascular disease in sickle cell disease. Clinical trials in sickle cell disease (focus on central nervous system and vaso-occlusive crisis)|
|Allen R. Chen, MD, PhD, MHS||JHU||Translational studies in BMT|
|Kenneth J. Cohen, MD, MBA||JHU||Clinical and translational neuro-oncology research|
|Yolanda M. Fortenberry, Ph.D.||JHU||Serpin biology in hemostat|
|Terry Fry, MD||NIH||Allogeneic immunotherapy, hematopoietic stem cell transplantation|
|Alan D. Friedman, MD||JHU||Transcriptional regulation of myeloid differentiation and action of myeloid oncoproteins|
|Christopher Gamper, MD, PhD||JHU||Regulation of T cell effector differentiation and tolerance|
|Lee J. Helman, MD||NIH||Molecular biology of pediatric solid tumor|
|Rosandra Kaplan, MD||NIH||Clincial studies aimed at targeting Tumor Microenvironmentl|
|Gregory Kato, MD||NIH||Translational studies in sickle cell disease|
|Jeffrey Keefer, MD, PhD||JHU||Regulation of fetal hemoglobin|
|Javed Khan, MD||NIH||Pediatric cancer genomics|
|Jason Levine, MD||NIH||Bioinformatic systems for translational research|
|David M. Loeb, MD, PhD||JHU||Molecular biology of AML and translational studies in sarcoma treatment|
|Crystal Mackall, MD||NIH||Immune reconstitution, immunotherapy|
|Melinda Merchant, MD||NIH||Translational trials in sarcomas, immunotherapy|
|Ido Paz-Priel, MD||JHU||Transcriptional Regulation in leukemia|
|Eric Raabe, MD, Ph.D||JHU||Identification of novel molecular targets and therapeutics in pediatric brain tumors|
|Allan E. Sison, M.D|
Bone marrow microenviornment interactions in leukemia
|Kathy Ruble, RN, CPNP, AOCN, PhD||JHU||Childhood cancer survivorship/health promotion|
|Donald Small, MD, PhD||JHU||Molecular biology of normal hematopoiesis and leukemia|
|John J. Strouse, MD||JHU||Complications and clinical trials in sickle cell disease and hemophilia, and epidemiology of pediatric melanoma|
|Heather Symons, MD||JHU||Translational studies in BMT; research in palliative care|
|Clifford Takemoto, MD||JHU||Transcription factors and growth factor signaling in hematopoietic development|
|Katherine Warren, MD||NIH||Neuro-oncology, neuro-imaging, and neurotoxicity research|
|Alan S. Wayne, MD||NIH||Targeted and immune-based therapies for hematopoietic malignancies|
|Brigitte Widemann, MD||NIH||Clinical pharmacology and new drug development for children with cancer and neurofibromatosis Type 1|
|Elias Zambidis, MD, PhD||JHU||Human developmental hematopoiesis and embryonic stem cell biology|